What we do

The EUMCA is the voice for ethical European manufacturers and suppliers of pharmaceutical grade cannabis. We also represent the interests of Pharmaceutical and healthcare organisations who have an interest in establishing their presence in this fast-evolving industry.  Our primary goal is to establish and promote a standardised, ethical market for medicinal cannabis throughout the whole of Europe 

We campaign to ensure that the legal, medicinal cannabis industry is represented at the highest level with Governments and regulators throughout the European Union. 

By engaging with European Governments and regulators, we can create credible, lasting partnerships and coherent policy frameworks.  These policies cover important issues relating to research, development, manufacturing, regulation, market conditions and patient access


As a membership organisation we work with our members to develop and present policies to European governments, reimbursement organisations and regulating authorities

We use specialist working groups and expert networks to cover most industry hot topics. These groups are made up of representatives of member companies with special interest and expertise in these areas. This means that we can react quickly to any new issues as they arise. It is these groups which help us to draw up respond to Government consultations.

Specialist Working Groups

The EUMCA runs the following specialist groups each holding quarterly meetings at venues agreed by those members attending. Events are a valuable networking opportunity, with time allocated at the start of each session for informal networking.

Research & Development


  • To promote a scientific and medical research policy that supports a standardised, ethical and sustainable use of medicinal cannabis medicines throughout Europe
  • To identify and access new opportunities for medicinal cannabis research and development with academia and EU national health systems.
  • To build an innovative open platform for knowledge exchange and collaboration between medicinal cannabis manufacturers.



  • Faced with legislation and decisions from the European Commission and the Court of Justice and widely disparate national laws, it has never been more important to keep up with these developments. 
  • In addition to medicinal cannabis-specific legislation, smaller and overseas-based companies need support to interpret and implement other changes that impact more widely such as competition law, EU employment developments, bribery and corruption, tax and patents and other intellectual property.
  • The group reviews recent and forthcoming changes and discuss in depth issues where Government consultation is ongoing or where urgent action may be necessary


Regulatory & Quality


  • The EUMCA Regulatory group hold regular information sharing and networking meetings for those members working in Regulatory Affairs, related disciplines or those with an interest in understanding more about current challenges impacting the industry.
  • Each meeting focuses on current hot topics and take the form of presentations and/or group discussions. External experts and Regulatory Authority personnel are often invited as appropriate.  Examples of recent topics include:
    • Production and GMP;
    • Pharmacovigilance;
    • Sales and marketing communications


Patient Access & Reimbursement


  • Working with national reimbursement institutions and at EU level to ensure rational reimbursement policies for medicinal cannabis medicines are paid for by health systems and health insurance companies.
  • Reducing the hurdles to the uptake medicinal cannabis in the EU and enable innovative products to reach patients in a timely manner.
  • Improving equal access to medicinal cannabis-based medicines to patients throughout the EU.
  • Work with governments and officials to communicate solutions to market access challenges.

Medical Education


  • To support healthcare professionals and patients in understanding the clinical benefits of medicinal cannabis medicines throughout Europe. 
  • To work with patient organisations to develop ethical, comprehensive educational materials which provided balanced, scientific information on the benefits of medicinal cannabis.
  • To create a transparent, credible and evidence-based knowledge exchange between medicinal cannabis stakeholders and patient organisations, ensuring that key communications are presented to patients in a standardised and ethical manner.

Business Development


  • A networking group for those members focussed on building their business by M&A, licensing, partnering and novel in-market strategies. In addition to networking time, content typically includes:
  • A member company showcasing their business and strategy;
  • Case histories of deals completed;
  • Contemporary topics affecting the marketplace;
  • Professional advice & services from member companies.
WP Feedback

Dive straight into the feedback!
Login below and you can start commenting using your own user instantly